Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, Brown BG.

Am J Cardiol. 2004 Feb 1;93(3):307-12.

PMID:
14759379
2.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
3.

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.

Am J Cardiovasc Drugs. 2008;8(2):69-81.

PMID:
18422390
4.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
5.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
6.

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group.

Arch Intern Med. 2002 Jul 22;162(14):1568-76.

PMID:
12123399
7.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
8.
9.

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ.

N Engl J Med. 2001 Nov 29;345(22):1583-92.

10.

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH.

Am J Cardiol. 2008 May 15;101(10):1428-36. doi: 10.1016/j.amjcard.2008.02.092.

PMID:
18471454
11.

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.

Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.

J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003.

12.

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.

Ellen RL, McPherson R.

Am J Cardiol. 1998 Feb 26;81(4A):60B-65B. Review.

PMID:
9526816
13.

Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.

Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD.

Arch Intern Med. 2000 Apr 24;160(8):1177-84.

PMID:
10789612
14.
16.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
17.

Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.

Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG.

Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1320-6.

19.

Safety of niacin and simvastatin combination therapy.

Bays H.

Am J Cardiol. 2008 Apr 17;101(8A):3B-8B. doi: 10.1016/j.amjcard.2008.02.026. Review.

PMID:
18375239
20.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA.

Circulation. 2004 Dec 7;110(23):3512-7. Epub 2004 Nov 10. Erratum in: Circulation. 2004 Dec 7;110(23):3615. Circulation. 2005 Jun 21;111(24):e446.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk